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Objective. Immune activation is associated with morbidity and mortality during human immunodeficiency virus (HIV) infec-
tion, despite receipt of antiretroviral therapy (ART). We investigated whether microbial translocation drives immune activation in 
HIV-infected Ugandan children.
Methods. Nineteen markers of immune activation and inflammation were measured over 96 weeks in HIV-infected Ugandan 
children in the CHAPAS-3 Trial and HIV-uninfected age-matched controls. Microbial translocation was assessed using molecular 
techniques, including next-generation sequencing.
Results. Of 249 children included, 142 were infected with HIV; of these, 120 were ART naive, with a median age of 2.8 years 
(interquartile range [IQR], 1.7–4.0 years) and a median baseline CD4+ T-cell percentage of 20% (IQR, 14%–24%), and 22 were 
ART experienced, with a median age of 6.5 years (IQR, 5.9–9.2 years) and a median baseline CD4+ T-cell percentage of 35% (IQR, 
31%–39%). The control group comprised 107 children without HIV infection. The median increase in the CD4+ T-cell percentage 
was 17 percentage points (IQR, 12–22 percentage points) at week 96 among ART-naive children, and the viral load was <100 copies/
mL in 76% of ART-naive children and 91% of ART-experienced children. Immune activation decreased with ART use. Children 
could be divided on the basis of immune activation markers into the following 3 clusters: in cluster 1, the majority of children were 
HIV uninfected; cluster 2 comprised a mix of HIV-uninfected children and HIV-infected ART-naive or ART-experienced chil-
dren; and in cluster 3, the majority were ART naive. Immune activation was low in cluster 1, decreased in cluster 3, and persisted 
in cluster 2. Blood microbial DNA levels were negative or very low across groups, with no difference between clusters except for 
Enterobacteriaceae organisms (the level was higher in cluster 1; P < .0001).
Conclusion. Immune activation decreased with ART use, with marker clustering indicating different activation patterns accord-
ing to HIV and ART status. Levels of bacterial DNA in blood were low regardless of HIV status, ART status, and immune activation 
status. Microbial translocation did not drive immune activation in this setting.
Clinical Trials Registration. ISRCTN69078957.
Keywords. HIV; children; microbial translocation; immune activation; sequencing; pediatrics; Africa.
 
In 2016, 160 000 children acquired human immunodeficiency 
virus (HIV) infection, approximately 90% of whom were 
in sub-Saharan Africa [1]. Untreated HIV infection results 
in chronic immune activation [2, 3] and associated poorer 
immune recovery, increased mortality, and increased morbidity 
[4, 5]. Immune activation influences CD4+ and CD8+ T cells, 
monocytes, and dendritic cells and is associated with increased 
expression of proinflammatory cytokines such as interleukin 1 
(IL-1) and tumor necrosis factor (TNF) [2, 6], polyclonal B-cell 
activation, and hypergammaglobulinemia [7, 8]. Immune acti-
vation can persist, albeit at lower levels, despite viral suppression 
with antiretroviral therapy (ART) [2, 9]. Because immune acti-
vation pathways may differ with regard to drivers and impact, 
depending on setting and age group, quantifying HIV-related 
immune activation involves measuring levels of a broad range 
of cellular, soluble, and inflammatory markers (eg, T-cell activa-
tion, TNF, and C-reactive protein [CRP]) [10].
The causes of immune activation in children are poorly charac-
terized. One potential driver is microbial translocation. It is pos-
tulated that depletion of intestinal CD4+ T cells during the early 
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stage of HIV infection allows increased microbial translocation 
from the gut, driving a chronic immune response [11, 12]. These 
microbial products include immunostimulants such as lipopoly-
saccharide (LPS), a component of gram-negative bacterial outer 
membranes, and 16S ribosomal DNA (rDNA), which is common 
to all bacterial species. Increased levels of circulating LPS are asso-
ciated with higher levels of immune activation in HIV-infected 
adults [4, 12]. Higher levels of LPS and 16S rDNA are associated 
with poorer immune restoration in patients receiving ART [11].
However, the evidence that microbial translocation drives 
immune activation is inconsistent, and quantification has 
proved challenging. 16S rDNA polymerase chain reaction 
(PCR) analysis can be contaminated by artifacts from endoge-
nous/exogenous bacteria [13, 14], and without sequencing the 
PCR product it is impossible to exclude contamination. Some 
studies have not found an association between microbial trans-
location and immune activation [15, 16]. Other studies have 
been cross-sectional or retrospective [17–20]. Translocation 
may be due to, rather than a cause of, severe HIV disease [21]. 
There are few data from Africa. One large African longitudinal 
study (performed in Uganda) found no significant increase in 
microbial translocation during untreated disease progression in 
adults; a high CRP level was associated with mortality without 
a high LPS level [22, 23]. Data in children are limited and lack 
consistent associations, such as between 16S rDNA/LPS and 
T-cell activation or inflammatory markers [24–28].
Although microbial translocation is an attractive hypothe-
sis, further longitudinal studies are needed, particularly among 
children in sub-Saharan Africa, since microbial translocation in 
HIV-infected children has not been consistently associated with 
cellular/soluble pathways of immune activation [24–27, 29]. We 
therefore investigated the impact of microbial translocation on 
cellular/soluble immune activation pathways and vascular dam-
age in Ugandan HIV-infected children, compared with findings 
in age-matched, HIV-uninfected controls, using a panel of molec-
ular techniques, including next-generation sequencing (NGS) of 
bacterial 16S rDNA in blood. We hypothesized that if microbial 
translocation drove immune activation in this cohort, we would 
detect significant differences in levels of plasma bacterial DNA 
between children with and those without immune activation.
METHODS
Study Population
We included HIV-infected children enrolled in Uganda in 
CHAPAS-3, a trial comparing the toxicity and efficacy of first-
line ART drugs (abacavir, zidovudine, or stavudine, given with 
lamivudine and either nevirapine/efavirenz; clinical trials reg-
istration ISRCTN69078957) [30]. Eligible children were ART 
naive or were ART experienced and had been receiving a stable 
stavudine-containing first-line ART regimen for >2 years with 
a viral load (VL) of <50 copies/mL. Age, ART, weight, height, 
and comorbidities were recorded longitudinally. Hematologic 
parameters, biochemical parameters, and CD4+ T-cell counts 
were measured at weeks 6, 12, and 24 and every 24 weeks there-
after; VL was measured in stored samples at 48 and 96 weeks 
(Supplementary Materials). At baseline and week 12 visits, 
whole-blood specimens were collected and, within 2 hours, 
were separated into cell pellets and plasma by centrifugation at 
1500×g for 15 minutes and stored at −80°C. For flow cytome-
try, whole-blood specimens were evaluated within 4 hours of 
collection.
The trial showed good clinical, virological, and immuno-
logical responses in all randomized groups, with a low level of 
toxicity [30]. For this substudy, we included all 120 ART-naive 
and 22 ART-experienced children recruited at the Joint Clinical 
Research Centre (Kampala, Uganda). A  total of 143 HIV-
uninfected controls were recruited for a single cross-sectional 
assessment from community well-child clinics (Kampala). 
These children had their HIV-uninfected status confirmed and 
were age matched (±1 year) at a ratio of 1:1 to enrolled HIV-
infected children during the recruitment phase. After clinical 
assessment of each child, a 10-mL frozen plasma specimen was 
collected and stored without cell pellets [31]; 109 had a suffi-
cient volume of plasma for evaluation by assays used in this 
study. For microbial translocation assays, these cross-sectional 
samples plus longitudinal samples collected from HIV-infected 
children at baseline (before ART initiation, for ART-naive chil-
dren) and weeks 12 and 72 were used. For markers of immune 
activation, samples collected at weeks 0 and 96 were used.
Microbial Translocation
Because broad-range 16S rDNA PCR analysis is vulnerable 
to contamination, we used a quantitative PCR (qPCR) panel 
targeting bacteria previously implicated in translocation (eg, 
Enterobacteriaceae species [32]), known gut bacteria (eg, 
Bifidobacterium species), and bacteria that could be gut derived 
or skin contaminants (eg, Staphylococcus aureus). Bacterial DNA 
was extracted from plasma and cell pellets (to detect phagocy-
tosed bacteria); qPCR was performed to detect Lactobacillus 
species, Bifidobacterium species, Fusobacterium species, 
Enterobacteriaceae organisms, S. aureus, Streptococcus pyogenes, 
and Staphylococcus species, and then broad-range 16S rDNA 
PCR was performed, as previously described (Supplementary 
Materials) [33]. qPCR sensitivity varied between assays, from 
0.1–1 to 1.3–13 colony-forming units (CFUs) per PCR run, 
using species-specific standards (Supplementary Table 1).
For broad-range 16S rDNA PCR, bacterial load (measured as 
the number of CFUs per PCR run) was quantified using stan-
dards of known concentrations (derived from Escherichia coli), 
and samples with equal or higher cycle thresholds than those of 
negative controls were considered to have negative results. Assay 
sensitivity was 5–50 CFUs per PCR reaction. CFUs and a rank-
ing scheme of test results (ie, strong positive to negative), rather 
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than copy numbers, were used because presentation of a single 
16S gene copy number can lead to overinterpretation, owing 
to variance of such data even within species (Supplementary 
Materials). NGS was performed according to the Illumina pro-
tocol, with modifications for samples with a low biomass level 
(Supplementary Materials).
Immune Activation and Inflammatory Markers
Because pathways between microbial translocation and markers 
of inflammation, cellular immune activation, and vascular dam-
age are not well characterized in this population, we selected a 
broad range of markers. Coagulation factor III (Tissue Factor), 
and D-dimer levels were quantified using commercial enzyme-
linked immunosorbent assay kits (R&D Systems, Technoclone) 
according to the manufacturers’ instructions. Levels of the fol-
lowing 17 biomarkers were assessed using MesoScale Discovery 
in accordance with the manufacturer’s protocols and were 
read using a QuickPlex SQ analyzer (MesoScale Discovery; 
Supplementary Table  2A) [31]: IL-1 receptor antagonist 
(IL-1RN), high-sensitivity CRP, TNF, interleukin 10, interleu-
kin 6, the chemokines CXCL8 (IL-8) and CCL2 (also known as 
monocyte chemoattractant protein 1), angiopoietin 1, angiopoi-
etin 2, E-selectin, P-selectin, the transmembrane glycoprotein 
ICAM-3, thrombomodulin, serum amyloid A, the glycoprotein 
SICAM-1, the cell adhesion molecule VCAM, and the growth 
factor VEGFA.
For cellular markers, 2 flow cytometry panels were used. 
First, the presence of HLA-DR+ and CD38+ was assessed in 
CD4+/CD8+ T-cell populations, to quantify activated (ie, dou-
ble-positive) T cells [3]. Second, proliferation of CD4+ T cells 
was quantified using Ki67 in naive (CD45RA+), recent thy-
mic emigrant (CD31+), and memory (CD45RA–CD31–) T 
cells. Flow cytometry was performed using the FACSCalibur 
platform (Becton-Dickinson; Supplementary Materials and 
Supplementary Table 2B) [31].
Statistical Analysis
Baseline characteristics were compared between ART-naive and 
ART-experienced HIV-infected children and matched control 
groups, using the χ2 or Fisher exact test (for binary data) and 
the Mann-Whitney U test (for continuous data). Paired baseline 
and week-96 levels of cellular, inflammation, cardiovascular 
injury and thrombogenesis markers were compared for HIV-
infected groups, using Wilcoxon signed rank tests. Associations 
between markers of immune activation and microbial translo-
cation were assessed using Spearman rho correlation analysis 
(Supplementary Materials).
Given the large number of baseline and week-96 laboratory 
parameters (age-associated CD4+ and CD8+ T-cell counts, 
viral load, inflammation biomarker levels, and immune acti-
vation and proliferation marker levels), we identified clusters 
of children with more-similar phenotypes, using principal 
components analysis (based on the correlation matrix), fol-
lowed by hierarchical clustering of the first 5 principal com-
ponents by use of Ward’s distance. We used baseline data from 
HIV-uninfected controls for baseline and week-96 analyses, 
assuming minimal change over time. Microbial translocation 
markers measured before randomization and at week 72 were 
compared across clusters. Pelleted samples were only availa-
ble from HIV-infected children and were therefore not used in 
clustering.
All statistical analyses were performed with R, version 
3.2.1. No formal adjustment was made for multiple testing, 
but results were interpreted on the basis of the strength of 
associations.
Ethical Considerations
The study was approved by UCL Research Ethics Committee 
(5019/001) and the Ugandan National Council for Science and 
Technology (HS1559). Written informed consent was obtained 
for storage and use of samples from caregivers, with participant 
assent obtained when appropriate.
RESULTS
This study recruited 285 children: 142 HIV-infected children 
(120 were ART naive, and 22 were ART experienced) and 143 
HIV-uninfected controls, of whom 109 had sufficient plasma 
specimens for all assays (89 were age matched to ART-naive 
children, and 20 were age matched to ART-experienced chil-
dren; Supplementary Materials). Two controls (age matched to 
ART-naive children) were excluded because they were statistical 
outliers with high levels of immune activation (Supplementary 
Materials). HIV-infected children had low and comparable tox-
icity rates in each randomized arm [30]. There were 3 deaths 
(due to measles, measles/pneumonia, and Kaposi sarcoma), all 
among ART-naive children, after 25, 38, and 56 weeks of ART. 
Four ART-naive patients were lost to follow-up by week 72; 1 
only had baseline samples, and the others were followed up for 
>24 weeks. Samples were available for microbial translocation/
immune activation assays for most children at each time point 
(Supplementary Table 3).
At enrollment, the ART-experienced group had received 
ART for a median of 4  years (interquartile range [IQR], 2.6–
4.3 years). ART-naive children were younger, had lower CD4+ 
T-cell counts and percentages, and lower levels of anthropo-
metric markers at baseline and showed greater gains over time, 
compared with ART-experienced children (Table 1). The ART-
naive group was approximately 6 months younger than controls; 
ART-experienced children and controls were similar in age. 
Both HIV-infected groups had lower CD4+ T-cell percentages 
than controls. The ART-naive group had lower anthropomet-
ric values than controls at baseline, whereas values were sim-
ilar between the ART-experienced group and HIV-uninfected 
controls.
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As expected, since ART-experienced children had virologi-
cal suppression at enrollment, more ART-experienced children 
(91%; 95% confidence interval [CI], 70%–99%) than ART-naive 
children (76%; 95% CI, 67%–83%) had a VL of <100 copies/mL 
at week 96, but the difference was not significant (P = .16).
Microbial Translocation
Most plasma samples from all groups tested negative by 
qPCR (Figure  1), with the exception of Enterobacteriaceae 
organisms and S.  aureus. Even in positive samples, levels 
were low. There was no significant difference between groups 
or over time in proportions of positive samples or in those 
testing weakly or strongly positive (P >  .05; Supplementary 
Figure  1A and 1B), except in proportions positive for 
Enterobacteriaceae organisms between ART-naive and age-
matched controls at baseline (23% [95% CI, 16%–32%] and 
37% [95% CI, 27%–48%], respectively; P = .03). Because pel-
let samples were only available for HIV-infected children, 
comparisons to controls were not possible. The proportions 
positive for S. aureus and Enterobacteriaceae organisms were 
higher for pellets than plasma samples in both HIV-infected 
groups: among ART-naive children, 52% of pellets (95% CI, 
42%–61%) and 10% of plasma specimens (95% CI, 5%–17%) 
were positive for S.  aureus, and 69% (95% CI, 59%–77%) 
and 23% (95% CI, 15%–32%), respectively, were positive for 
Enterobacteriaceae species; among ART-experienced chil-
dren, 64% of pellets (95% CI, 41%–83%) and 23% of plasma 
specimens (95% CI, 8%–45%) were positive for S.  aureus, 
and 59% (95% CI, 36%–79%) and 36% (95% CI, 18%–62%), 
respectively, were positive for Enterobacteriaceae species.
Results of broad-range 16S rDNA PCR of plasma samples 
were similar across groups and time points and revealed no 
difference between HIV-infected and HIV-uninfected children 
at baseline (median value, 100 CFU equivalents (IQR, 23–204) 
and 102 CFU equivalents (IQR, 46–148) among ART-naive 
children and their age-matched controls, respectively [P = .45], 
and 133 CFU equivalents (IQR, 77–185) and 104 CFU equiva-
lents (IQR, 53–152) among ART-experienced children and their 
age-matched controls, respectively [P  =  .25]; Supplementary 
Figure  1C). Pellets had higher median bacterial loads than 
plasma samples (1190 CFU equivalents [IQR, 440–2290] vs 113 
CFU equivalents [IQR, 33–200]; P < .0001), but bacterial loads 
Table 1. Characteristics of Antiretroviral (ART)–Naive and ART-Experienced Human Immunodeficiency Virus (HIV)–Infected Children and Age-Matched 
HIV-Uninfected Controls
Characteristic
HIV-Infected Children HIV-Uninfected Children
ART  
Naive  
(n = 120)
ART  
Experienced  
(n = 22) P
Matched to  
Naive Group  
(n = 87)
P
(vs ART-
Naive Group)
Matched to ART- 
Experienced 
Group (n = 20)
P
(vs ART-  
Experienced  
Group)
Male sex 59 (49) 10 (45) .82 40 (46) .67 12 (60) .37
Age, y 2.8 (1.7–4.0) 6.5 (5.9–9.2) <.001 3.3 (2.4–4.4) .004 6.3 (5.7–8.9) .89
Baseline CD4+ T-cell  
count, cells/mm3
922 (637–1451) 1188 (928–1813) .02 1361 (1039–1728) <.001 1010 (856–1343) .11
Baseline CD4+ T-cell  
percentage
20 (14–24) 35 (31–39) <.001 38 (34–43) <.001 40 (35–45) .06
Baseline viral load,  
copies/mL
386 800  
(166 500–1 800 000)
<100 NA NA NA
Change in CD4+ T-cell  
count from baseline t 
o wk 96, cells/mm3
314 (−38–657) −157 (−438–59) <.001 NA NA
Change in CD4+ T-cell  
percentage from  
baseline to wk 96
17 (12–22) 3 (0–6) <.001 NA NA
Viral load <100 copies/mL 
at wk 96
84/111 (76) 19/21 (91) .16 NA NA
Baseline weight-for-age  
z score
−2.0 (−3.2 to −0.9) −1.5 (−2.2 to −0.4) .05 −0.6 (−1.2–0.1) <.001 −1.0 (−2.1 to −0.1) .57
Baseline height-for-age 
 z score
−2.5 (−3.5 to −1.3) −1.5 (−2.1 to −1.1) .02 −0.8 (−2.1–0.1) <.001 −1.3 (−2.5 to −0.3) .52
Weight-for-age z score  
change from baseline  
to wk 96
1.0 (0.2–1.9) −0.1 (−0.2–0.0) <.001 NA NA
Height-for-age z score 
change from baseline  
to wk 96
0.8 (0.2–1.3) −0.1 (−0.3 to −1.4) <.001 NA NA
Data are no. or proportion (%) of children or median (interquartile range). Categorical variables were compared using the χ2 or Fisher exact test, and continuous variables were compared 
using the Mann-Whitney U test.
Abbreviation: NA, not applicable.
Microbial Translocation in Ugandan Children • JID 2019:219 (1 January) • 93
in pellets were similar in ART-naive and ART-experienced chil-
dren (P = .65).
For NGS, 168 of 655 samples (26%; 105 of 140 pellets [75%] 
and 63 of 515 plasma samples [12%]) had sufficient quantities of 
the amplified 16S library to ensure successful sequencing. None 
of the 113 plasma samples from HIV-uninfected controls were 
sequenced successfully, as an insufficient quantity of the library 
was produced. After removing operational taxonomic units 
(OTUs) seen in negative experimental controls (Supplementary 
Materials), OTU numbers were sparse and dominated by 
Enterobacteriaceae organisms and staphylococci in both HIV-
infected groups. Veillonellaceae, Clostridiaceae, Bacteroidaceae, 
and Bifidobacteriaceae organisms were also represented in low 
frequencies in both groups (Figure  2). Principal coordinates 
analysis (performed by the weighted Unifrac method [34]) 
revealed no clustering by ART-naive or ART-experienced status 
or by time point (Supplementary Figure 2).
Immune Activation Markers
Levels of most cellular and humoral markers of immune acti-
vation, cardiovascular injury, and disordered thrombogenesis 
decreased significantly over time in the ART-naive group after 
ART initiation (Supplementary Table  4), except for D-dimer, 
angiopoietin 1 and 2, serum amyloid A, CXCL8, and IL-1RN 
(IL-1RA). For ART-experienced children, there were significant 
although less marked decreases in proliferating recent thymic 
emigrants (as measured by the CD45RA+CD31+Ki67+ cell per-
centage) and proliferating memory cells (as measured by the 
CD45RA–CD31–Ki67+ cell percentage), ICAM-3, interleukin 
6, CCL2, VCAM, angiopoietin 2, and VEGFA. Compared with 
controls, all markers were higher in ART-naive children at base-
line (P < .001), except for IL-1RN, angiopoietin 1, and coagu-
lation factor III. Although ART-experienced children also had 
significantly higher levels of immune activation markers than 
controls in most assays (P < .0001), the differences were smaller. 
For several cardiovascular injury and disordered thrombo-
genesis markers (angiopoietin 1, E-selectin, ICAM-1, VEGFA, 
D-dimer, and thrombomodulin), there were no differences 
between ART-experienced children and controls with regard to 
levels of 3 inflammatory markers (CXCL8, serum amyloid A, 
and TNF) and markers of 1 cellular immune activation path-
way (double-positive activated CD4+/CD8+ T cells). There was 
minimal correlation between immune activation and micro-
bial translocation markers at early or late time points among 
HIV-infected ART-naive children and among HIV-infected 
ART-experienced children, and if any association was observed 
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Figure 1. Quantitative polymerase chain reaction (qPCR) results over time ranked by negative to strong positive. Colony-forming unit (CFU) equivalents as compared to cycle 
threshold values of standards with a known CFU quantity and categorized from negative to strong positive. For each category, the total percentage of positive samples (ie, 
those with a result > 0) is equal to 100% minus the percentage of negative samples, shown at the left of each subpanel. ART, antiretroviral therapy.
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(eg, in the ART-experienced group, there was an association 
between 16S rDNA detection and the TNF level at week 96), it 
was inconsistent across time points (Supplementary Figure 3).
Immune Activation Clusters
Based on values of the 19 markers of immune activation at enroll-
ment (for all children) and week 96 (for HIV-infected children), 
children could be grouped into 3 distinct clusters that reflected 
different intrinsic phenotypes. Cluster 1 (n = 109) mostly com-
prised ART-experienced and HIV-uninfected children, clus-
ter 2 (n = 33) included HIV-uninfected controls and children 
from both HIV-infected groups, and cluster 3 (n = 107) mostly 
included ART-naive children (Table  2 and Supplementary 
Figure 4). Cluster 1 had low levels of markers of immune activa-
tion at baseline and (for HIV-infected children) at week 96. The 
factors distinguishing cluster 2 were persistent immune acti-
vation at week 96, particularly in biomarkers of inflammation, 
cardiovascular injury, and disordered thrombogenesis, with 
less persistence of cellular markers (Supplementary Table  5, 
Figure 3, and Supplementary Figure 5). Cluster 3 had high lev-
els of immune activation at week 0, which decreased by week 96 
(Supplementary Figure 5). Of note, VL suppression at week 96 
was less common in HIV-infected children in cluster 2 (3 of 13 
[23%]) than those in cluster 3 (80 of 98 [83%]; P < .0001).
Markers of microbial translocation were low and similar 
across clusters, except for Enterobacteriaceae organisms: 48 of 
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Figure 2. Results of next-generation sequencing. Positive controls are mock communities (Supplementary Materials). Phylogenetic tree, by antiretroviral therapy (ART) 
group (experienced or naive). Negative control operational taxonomic units (OTUs) were removed (rarefied), showing sparse OTUs, including Staphylococcaceae among other 
families. OTUs derived from both ART-experienced and ART-naive samples are distributed across the phylogenetic tree.
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109 children (44%) in cluster 1 were positive for these organ-
isms, compared with 7 of 33 (21%) and 21 of 107 (20%) in clus-
ters 2 and 3, respectively (P < .0001), a difference that remained 
at week 72 (Table 2). There was no evidence of differences across 
clusters in the proportions with positive results of the other 
microbial assays (P > .05).
DISCUSSION
In this large, prospective study, with follow-up for >2 years and 
inclusion of HIV-uninfected controls, we aimed to evaluate the 
relationship between immune activation and microbial trans-
location in HIV-infected and uninfected children in Uganda. 
We used a wide range of cellular/soluble biomarkers to assess 
immune activation and comprehensively evaluated blood-
stream bacterial DNA, using specific and broad-range PCR 
analyses alongside NGS. Plasma bacterial DNA was detected at 
very low levels, with minimal differences between HIV-infected 
and uninfected children or between ART groups or over time 
except for Enterobacteriaceae organisms, which were found in 
a higher proportion of controls than ART-experienced children 
at baseline. Where bacterial DNA was present, there was no 
association with levels of immune activation.
Immune activation decreased over time in most ART-naive 
children, and markers of immune activation tended to be lower 
in ART-experienced than ART-naive children, making them 
more similar to age-matched controls, as expected. Cluster anal-
ysis identified a group of ART-naive children (cluster 3) with 
immune activation decreasing over time along with viral load, 
but it also identified a group (cluster 2), comprising ART-naive, 
ART-experienced, and HIV-uninfected children, with high 
Table 2. Characteristics and Microbial Translocation Markers, by Cluster Group
Characteristic Cluster 1 (n = 109) Cluster 2 (n = 33) Cluster 3 (n = 107) P
Percentage of all children 44 13 43
ART status at baseline, no. (%) <.0001
 Experienced 16 (15) 3 (9) 3 (3)
 Naive 6 (5) 10 (30) 104 (97)
 HIV uninfected 87 (80) 20 (61) 0 (0)
Viral load among HIV-infected children
 Baseline 100 (100–245) 606 275 (10 6390–1 998 000) 336 520 (141 390–949 650) <.0001
 Wk 96 100 (100–100) 171 (110–61 190) 100 (100–110) <.0001
Virological suppressiona at wk 96 <.0001
 Yes 20 (19) 3 (3) 80 (78)
 No 2b (7) 9 (31) 18 (62)
 HIV uninfected 87 (81) 20 (19) 0 (0)
 Viral load data missing 0 (0) 1 (10) 9 (90)
Bacterial data
 Baseline 109 33 107
  I-FABP level, pg/mL 118 (59 -222) 100 (57–165) 86 (40–138) .008
  16S rDNA positivity 99 (92) 28 (85) 84 (79) .32
  Bifidobacterium positivity 0 (0) 0 (0) 6 (6) .02
  Staphylococcus aureus positivity 9 (8) 4 (12) 10 (9) .68
  Streptococcus pyogenes positivity 0 (0) 1 (3) 0 (0) .13
  Fusobacterium positivity 1 (1) 0 (0) 0 (0) .99
  Enterobacteriaceae positivity 48 (44) 7 (21) 21 (20) <.0001
  Staphylococcus positivity 1 (1) 1 (3) 1 (1) .51
  Lactobacillus positivity 1 (1) 0 (0) 0 (0) .99
 Wk 72 109 33 106
  I-FABP level, pg/mL 150 (80–234) 159 (99–194) 146 (82–195) .83
  16S rDNA positivity 101 (93) 30 (91) 103 (96) .18
  Bifidobacterium positivity 0 (0) 0 (0) 0 (0)
  Staphylococcus aureus positivity 3 (3) 0 (0) 5 (5) .26
  Streptococcus pyogenes positivity 0 (0) 1 (3) 0 (0) .13
  Fusobacterium positivity 1 (1) 1 (3) 1 (1) .51
  Enterobacteriaceae positivity 48 (44) 3 (9) 31 (29)  .001
  Staphylococcus positivity 0 (0) 0 (0) 0 (0)
  Lactobacillus positivity 0 (0) 0 (0) 1 (1) .55
Data are no. (%) of children or median (interquartile range). Categorical variables were compared using the χ2 or Fisher exact test, and continuous variables were compared using the Mann-
Whitney U test.
Abbreviations: HIV, human immunodeficiency virus; I-FABP, intestinal fatty acid binding protein; rDNA, ribosomal DNA.
aDefined as <100 copies/mL.
bViral loads were 935 and 2140 copies/mL.
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levels of immune activation. In both groups there was minimal 
association with microbial translocation. This suggests that, in 
a Ugandan setting, there may be causes of immune activation 
beyond either microbial translocation or HIV itself.
Techniques used for detecting microbial translocation are 
contentious. Previous studies have used LPS, soluble CD14 (a 
marker of monocyte activation), lipoteichoic acid (a compo-
nent of gram-positive cell walls), lipopolysaccharide-binding 
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Figure 3. Box plots of log concentrations of tumor necrosis factor, activated CD4+ T cells (defined as, T cells double positive for HLA-DR and CD38), and high-sensitivity 
C-reactive protein, by cluster group, at baseline (week 0; left column) and week 96 (right column). P values were determined by the Kruskal-Wallis test. For concentrations of 
the complete set of biomarkers, see Supplementary Figure 5.
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protein (an acute-phase protein that binds LPS), and endo-
toxin core antibody (an antibody to LPS) as proxy markers 
of microbial translocation during HIV infection, with diver-
gent, inconsistent results in comparison to clinical outcome, 
immune activation, and each other [11, 12, 16, 22, 24, 27–29, 
35, 36]. Given the challenges in reproducibility and heterogene-
ity in previous studies [22, 29, 35, 37], we did not use LPS and 
instead focused on comprehensive evaluation of bacterial DNA. 
Broad-range 16S rDNA PCR has also shown conflicting results 
(Supplementary Materials). Even with sequencing, prior stud-
ies have not conclusively identified gut bacterial DNA in the 
bloodstream at levels greater than those of potential contami-
nants [11, 20, 32, 35]. By using a panel of molecular microbial 
techniques, including a modified broad-range 16S rDNA PCR 
assay used clinically for >15 years [13] and NGS, we combined 
sensitivity (from the qPCR assays) with specificity (from NGS) 
to identify bacterial species in the bloodstream that might have 
been derived from the gut.
The most consistently detected bacterial species across all 
groups was S. aureus, which could have been derived from the 
gut or a skin contaminant (despite efforts to minimize contam-
ination). Without sequencing, it is difficult to extrapolate the 
degree to which previously demonstrated high frequencies of 
16S rDNA positivity may have been due to skin contamina-
tion by S. aureus or other skin-colonizing bacteria, rather than 
to gut translocation. Using NGS, bacteria were identified that 
could be consistent with microbial translocation from the gut, 
such as Veillonella species and Fusobacterium species. However, 
they were found at very low levels in both ART-naive and ART-
experienced children at baseline (Supplementary Figure 2).
Enterobacteriaceae organisms were found in HIV-infected 
individuals during 2 previous studies that used sequencing 
methods [20, 32]. Although in this study, Enterobacteriaceae 
species were detected using both qPCR and NGS, the fre-
quency of detection by qPCR was consistently low over time 
(and lower than was considered clinically significant in previ-
ous use of the assay [38]) in both HIV-infected groups, indi-
cating that the results may have been due to contamination. 
Enterobacteriaceae species are unlikely to be driving immune 
activation, because the ART-naive group experienced a dimi-
nution of immune activation over time and because positivity 
rates were higher in HIV-uninfected controls than cases at 
baseline (37% vs 23%; P = .03). Furthermore, given minimal 
differences between other groups, the assay’s inherent vari-
ability, and its vulnerability to contamination, these results 
may be false positives. However, the possibility remains that 
findings reflect levels of microbial translocation in both HIV-
infected and uninfected groups that are low but not linked 
to immune activation. Given this possibility, despite previ-
ous provisos, the detection of Enterobacteriaceae organisms 
in more controls than HIV-infected children merits further 
investigation.
We were unable to sequence DNA in any plasma samples from 
HIV-uninfected controls, likely because of insufficient DNA 
present despite similar sample volumes, which may mean that 
there is a biologically significant difference in the quantities of 
bacterial DNA between HIV-infected and uninfected groups, as 
found in previous studies that used broad-range 16S rDNA PCR 
(without sequencing) [11, 20]. We did not have pellets available 
for controls, which in general yielded higher quantities of DNA 
for each assay, possibly because of detection of phagocytosed 
bacteria or due to the process of pelleting concentrating bacte-
rial DNA. In future studies, pellets may be more useful in eval-
uating microbial translocation than plasma samples. However, 
it is important to emphasize that, even in pellets, despite lower 
immune activation, ART-experienced children had levels of 
bacterial DNA similar to those in ART-naive children. Future 
studies must consider the challenges associated with interstudy 
comparisons, as described in the Supplementary Materials.
From this comprehensive evaluation of bacterial DNA in the 
bloodstream of HIV-infected and HIV-uninfected children in 
Uganda, there is little evidence that microbial translocation is 
occurring at biologically significant levels or that it is driving 
immune activation, because markers of immune activation 
(along with viral load) fell significantly over time during ART 
but no difference was seen in levels of microbial DNA. This con-
clusion supports the finding that trials aiming to modify micro-
bial translocation have not yet demonstrated clinically relevant 
improvements in HIV infection [39, 40]. Therefore, alternative 
modifiable causes of immune activation should be considered 
in this setting [9, 41], including HIV itself, via proteins such 
as Nef and gp120 [42, 43]; release from inhibition by regula-
tory mechanisms, such as the activity of T-regulatory cells [44]; 
other infections (both acute and chronic); and malnutrition. 
These may be more important than microbial translocation in 
driving immune activation.
Coinfections and malnutrition are of particular interest 
because children in cluster 2 had immune activation regard-
less of HIV/ART status. Acute and chronic infections sig-
nificantly associated with immune activation during HIV 
infection include cytomegalovirus infection, malaria, tubercu-
losis, Candida infection, herpes zoster, and visceral leishman-
iasis [45–49]. The association between these infections and 
immune activation in HIV-uninfected African children merits 
further investigation because there may be an opportunity to 
improve health outcomes beyond specifically targeting HIV. 
Malnutrition and environmental enteropathy may, independent 
of HIV, also drive immune activation [50].
Study limitations include the availability of baseline pellets 
only for HIV-infected children; these samples had higher yields 
of bacterial DNA and were more likely to be sequenced success-
fully by NGS. In future studies, the advantages of cell pellets 
over plasma specimens for bacterial NGS should be consid-
ered. Samples from only 1 time point were available for control 
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children, so their results were used twice in the clustering anal-
ysis, based on the assumption that they had minimal changes 
over time. Acute infection was an exclusion criterion for con-
trol children, but some acute infections may have been missed. 
However, for HIV-infected children, the study was relatively 
large, including 142 children followed for 96 weeks.
In conclusion, based on comprehensive characterization of 
bacterial DNA in the bloodstream of HIV-infected children in 
Uganda as compared to controls from the same community, 
microbial translocation appeared to be low in HIV-infected 
children, regardless of receipt of ART and over time, whereas 
immune activation decreased over time in children com-
mencing ART. A  small but significant cluster of children had 
persistent immune activation regardless of HIV/ART status. 
Drivers of immune activation other than microbial transloca-
tion in both HIV-infected and HIV-uninfected children merit 
further investigation in African settings.
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